Stephens Consulting’s Immunome IMNM Stock Holding History

Stephens Consulting’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$337	–	1567
2025 Q1	$337	Buy	+50	New	+$480	﹤0.01%	1399

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Stephens Consulting's IMNM Position: Q2 2025 in Review

Stephens Consulting sold out of Immunome (IMNM) in Q2 2025, closing a stake of 50 shares — an estimated $337 sold.

Stephens Consulting first reported a position in IMNM in Q1 2025 and held it in 1 quarter. The position peaked at $337 in Q1 2025. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

Stephens Consulting reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 50 Immunome shares in Q2 2025, an estimated $337.
Stephens Consulting first reported a position in Immunome in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Immunome position peaked at $337 in Q1 2025.
142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.